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Abstract: Pyrrolopyrimidines are an important class of natural products with a broad spectrum of
biological activities, including antibacterial, antifungal, antiviral, anticancer or anti-inflammatory.
Here, we present the identification of a biosynthetic gene cluster from the rare actinomycete strain
Kutzneria albida DSM 43870, which leads to the production of huimycin, a new member of the
pyrrolopyrimidine family of compounds. The huimycin gene cluster was successfully expressed in
the heterologous host strain Streptomyces albus Del14. The compound was purified, and its structure
was elucidated by means of nuclear magnetic resonance spectroscopy. The minimal huimycin gene
cluster was identified through sequence analysis and a series of gene deletion experiments. A model
for huimycin biosynthesis is also proposed in this paper.
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1. Introduction
Pyrrolopyrimidines are a class of natural products characterized by the presence of a 7-deazapurine
moiety in their structures [1]. This class of compounds is widely spread among three domains of life:
archaea, bacteria, and eukarya [1]. The study of pyrrolopyrimidines began in 1956 with the discovery of
an anti-Candida compound, toyocamycin, in the culture broth of Streptomyces toyocaensis [2]. Soon after
the discovery of toyocamycin, other secreted 7-deazapurine compounds, tubercidin and sangivamycin,
were isolated from the culture filtrates of Streptomyces tubercidicus and Streptomyces rimosus [3,4].
To date, more than 30 different 7-deazapurines have been isolated from various biological sources,
including bacteria, cyanobacteria, red algae, marine sponges, and tunicates [1]. In addition to
secreted pyrrolopyrimidines, which act as natural products, pyrrolopyrimidines can also be found as
modified bases in tRNA. Queuosine is one of the most studied modified nucleosides that contains a
7-deazapurine moiety [5]. It is present in the wobble position of aspartyl, asparaginyl, histidyl and
tyrosyl tRNA, where it likely modifies base pairing characteristics of tRNA and enhances translational
efficiency [6–8]. Distributed ubiquitously among prokaryotes and eukaryotes, queuosine cannot be
found in archaebacteria. In archaeal species, archeosine, a noncanonical 7-deazapurine nucleoside,
is incorporated into tRNA [9].
Secreted pyrrolopyrimidines often possess antibacterial, antifungal, anticancer, antiviral
or anti-inflammatory activities [1,10–12]. Their structural similarity to purine bases allows
7-deazapurines to interfere with various cellular processes involving nucleotides and nucleosides [1].
For instance, toyocamycin and tubercidin have been shown to be substrates of mammalian adenosine
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kinase [13]. In the phosphorylated form, toyocamycin is recognized by mammalian DNA and RNA
polymerases and can become incorporated into DNA and RNA [14]. Although pyrrolopyrimidines
are not substrates for amino acid aminoacylation, toyocamycin and sangivamycin inhibit this
process [15]. When incorporated into the acceptor stem of tRNA, pyrrolopyrimidine inhibits tRNA
aminoacylation [15]. Sangivamycin has recently been demonstrated to inhibit protein kinases [16,17].
A broad range of biological activities characteristic of pyrrolopyrimidines makes them promising
potential drug leads for the pharmaceutical industry. Recent U.S. food and drug administration (FDA)
approval of ribociclib and baricitinib, which both contain a 7-deazapurine moiety, for the treatment
of breast cancer and rheumatoid arthritis further emphasizes the pharmaceutical importance of the
pyrrolopyrimidine class of compounds [18,19].
In this study, we report the identification and heterologous expression of a biosynthetic gene
cluster of Kutzneria albida DSM 43870 that encodes a new member of the pyrrolopyrimidine family
of natural products, huimycin. The compound was isolated, and its structure was elucidated using
extensive 2D nuclear magnetic resonance spectroscopy (NMR). Through a series of DNA deletion
experiments, the minimal cluster required for huimycin biosynthesis was determined. Based on the
cluster analysis, we also propose the biosynthetic route that produces huimycin.
2. Materials and Methods
2.1. Strains and BACs
All of the strains used in this study are listed in Table S1. The BACs are listed in Table S2.
Escherichia coli strains were cultured in LB medium [20]. For sporulation and conjugation, Streptomyces
strains were cultivated on soya flour mannitol agar (MS agar) [21] and in liquid tryptic soy broth (TSB;
Sigma-Aldrich, St. Louis, MO, USA). DNPM medium was used for secondary metabolite production
liquid [22]. The antibiotics ampicillin, kanamycin, apramycin, hygromycin and nalidixic acid were
supplemented when required.
2.2. DNA Manipulation
Isolation of DNA and all subsequent manipulations were performed according to standard
protocols [20]. BAC extraction from the genomic library of K. albida was performed using the
BACMAX™ DNA purification kit (Lucigen, Middleton, WI, USA). Restriction endonucleases were
used according to manufacturer’s recommendations (New England Biolabs, Ipswich, MA, USA). All of
the primers used in this study are listed in Table S3.
To determine the minimal huimycin biosynthetic cluster a series of BACs with the deletions of
single and multiple genes was constructed. In the BACs 2I16_LS and 2I16_RS large DNA regions
upstream and downstream of the putative huimycin cluster were deleted. In the BACs 2I16_4069,
2I16_4074, 2I16_4075, and 2I16_4076, the genes KALB_4069, KALB_4074, KALB_4075, and KALB_4076
were inactivated. In the BAC 2I16_LS 20 kb DNA fragment upstream of the huiA gene was deleted.
For this purpose, the hygromycin gene was amplified from the pACS-hyg plasmid with the LS-F/LS-R
pair of primers. The obtained PCR fragment was used for the Red-ET modification of the BAC
2I16 [23]. The constructed BAC 2I16 was checked by restriction mapping (Figure S1) and PCR with the
LS_chF/LS_chR pair of primers with subsequent sequencing of the obtained PCR product.
The BACs 2I16_RS, 2I16_4069, 2I16_4074, 2I16_4075 and 2I16_4076 were constructed in a similar
manner. Here, ampicillin resistance marker was used for recombineering purposes instead of
hygromycin marker. The marker was amplified from the pUC19 plasmid with the pairs of primers
RS_F/RS_R, 4069_F/4069_R, 4074_F/4074_R, 4075_F/4075_R, and 4076_F/4076_R. The obtained PCR
products were utilized for the construction of the abovementioned BACs using Red-ET modification.
The construction of the BACs was confirmed using restriction mapping (Figure S1), PCR with
the pairs of primers RS_chF/RS_chR, 4069_chF/4069_chR, 4074_chF/4074_chR, 4075_chF/4075_chR,
4076_chF/4076_chR, and sequencing.
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2.3. Metabolite Extraction and Analysis
Streptomyces albus strains containing 2I16 BAC and its derivatives were grown in 15 mL of TSB
medium for 24 h. One mL of the seed culture was used for inoculation of 100 mL of DNPM medium.
The cultures were cultivated for seven days at 28 ◦C. Huimycin was extracted with the equal amount
of butanol from the culture supernatant, evaporated, and dissolved in methanol.
For mass determination a Bruker Amazon Speed and a Thermo LTQ Orbitrap XL mass spectrometer
were used. Both machines were coupled to UPLC Thermo Dionex Ultimate3000 RS. Analytes were
separated on a Waters ACQUITY BEH C18 Column (1.7 µm, 2.1 mm × 100 mm) with water +0.1%
formic acid and acetonitrile +0.1% formic acid as the mobile phase.
2.4. Huimycin Isolation and NMR Data Acquisition
Streptomyces albus 2I16 was cultivated into 20 L of DNPM medium at 28 ◦C for seven days.
The mycelial part was separated by centrifugation. The supernatant was extracted once with the equal
amount of butanol. The solvent was evaporated under vacuum in a rotary evaporator. The huimycin
was purified using size-exclusion and reverse phase chromatography. Size-exclusion chromatography
was performed using Sephadex LH-20 (GE Healthcare, USA) and methanol as a solvent. The HPLC
separation was performed on semipreparative HPLC (Dionex UltiMate 3000, Thermo Fisher Scientific,
USA) equipped with a C18 column (Synergi 10 µm, 250 × 10 mm; Phenomenex, Aschaffenburg,
Germany). Water +0.1% formic acid and acetonitrile +0.1% formic acid were used as the mobile phase.
NMR spectra were recorded in meod4 at 500 MHz on a Bruker Avance 500 spectrometer (Bruker,
BioSpin GmbH, Rheinstetten, Germany) equipped with a 5 mm TXI cryoprobe. HSQC, HMBC, 1H-1H
COSY, and 2D TOCSY experiments were acquired using standard pulse program. CNST13 of HMBC
were set as 2,3JC-H = 2,8 and 10 Hz.
2.5. Genome Mining and Bioinformatics Analysis
The K. albida genome was screened for secondary metabolite biosynthetic gene clusters using
the antiSMASH online tool [24]. Geneious R9 (Biomatters Ltd.) software package was used for DNA
sequence analysis.
3. Results and Discussion
3.1. Identification of the Huimycin Gene Cluster Through Its Heterologous Expression in
Streptomyces albus Del14
Recently, we reported the complete genome sequence of Kutzneria albida DSM 43870 (GenBank
accession number NZ_CP007155), which is a representative of a rarely observed genus in the
Pseudonocardiaceae family [25]. Forty-six putative clusters encoding secondary metabolites were
identified in the genome of this strain [25]. To enable analysis of these metabolites, a genomic library
of K. albida was constructed using an integrative BAC vector. In the course of systematic activation of
cryptic secondary metabolite clusters from K. albida, a cluster annotated by the antiSMASH genome
mining software as “nucleoside biosynthetic cluster” was expressed in the heterologous host strain
S. albus Del14. For this purpose, a BAC 2I16 vector containing the cluster was isolated from the
constructed genomic library and transferred into the chassis strain S. albus Del14 by conjugation.
The obtained exconjugant strain S. albus 2I16 and the corresponding control strain without the BAC
S. albus Del14 were fermented in the production medium DNPM. The culture filtrate of the strains was
extracted with butanol, and the extracts were analyzed by liquid chromatography–mass spectrometry
(LC-MS). This analysis revealed a new peak in the extract of S. albus 2I16 as a result of the cluster
expression (Figure 1). Subsequent analysis of the extract using high resolution LC-MS revealed that the
identified peak corresponded to a compound with an [M + H]+ of 393.15 m/z (Figure 1). The extract
of the control strain S. albus Del14 did not contain the identified ion. A search in a natural product
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database for the identified high-resolution mass did not generate any matches, implying that the
identified compound might be new.
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3.2. Isolation and Structure Elucidatio of the Huimycin
To obtain structural information about the potentially new compound obtained from the
heterologous expression of the nucleoside gene cluster, we set out to purify it. For this purpose, the
S. albus 2I16 strain with the expressed nucleoside gene cluster was inoculated into 20 L of DNPM
medium, and the culture broth was extracted with butanol. The compound was separated from
contaminants in the extract using size-exclusion and reverse-phase chromatography. A total of 8.2 mg
of the compound was isolated during the purification process and was used for subsequent structure
elucidation purposes (Figures S2–S9).
The combination of the 1H NMR spectrum with the HSQC data indicated an isolated aromatic
signal, one anomeric methine, one methoxy signal together with three oxygenated methines and one
methylene signal as well as a methyl group. The TOCSY and COSY spectra suggested the presence of
a sugar moiety, which was determined to be 1-amino-2-deoxy-glucose by means of analyzing HMBC
cross peaks. HMBC correlations from H-2′ and H-9′ to C-8′ further revealed the substitution of an
acetate on the amino group of the sugar (Table 1). The large coupling constant observed for the
anomeric proton of the glucose moiety at 5.28 (d, J = 9.6 Hz) suggested its β-orientation. Further ROESY
correlations were observed between H1′/H3′/H5′ as well as H2′/H4′ of the glucose moiety.
The constitution of the aglycone core was determined to be a purine bearing substitutions at
C-2, C-6 and C-7. Several HMBC experiments with different long-range coupling constants (CNST13)
were used to link the substitutions to the correct positions. The HMBC spectrum acquired with
CNST13 = 2 Hz showed a more intense cross peak from the H-8 to a carbon at δ 160.3 than what was
observed in the HMBC with 10 Hz data, suggesting that the carbon at δ 160.3 (C-2) is the furthest carbon
from H-8 and shows a five bond correlation. Furthermore, according to HMBC, the alpha proton of
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the sugar moiety showed correlation with C-2, indicating its linkage. The methoxy group was found
to be linked on C-6 because of the HMBC correlation (in CNST13 = 2 Hz data) of methyl protons to
C-5 (at δ 98.7 ppm), showing a four-bond heteronuclear correlation. Due to the biosynthetic similarity
of this molecule to toyocamycin and their NMR data similarity, the cyano-group was deduced to be
attached to C-7. This was supported by the HMBC correlation from H-8 to carbon at δ 116.3 (C-10) and
the chemical shift of C-7 at δ 84.5 ppm.
Table 1. Nuclear magnetic resonance spectroscopy data of huimycin.






8 131.0 7.60, s 2 e, 4, 5, 6 e, 7, 10
10 116.3
11 54.2 4.05, s 5 e, 6
1′ 83.6 5.28, d 9.6 2, 2′, 3′, 5′
2′ 56.1 3.87 d 1′, 3′, 8′
3′ 76.3 3.55, m 2′, 4′
4′ 71.9 3.38 d 5′, 6′
5′ 79.2 3.39 d
6′ a 62.6 3.69, m 4′
6′ b 3.85 d
8′ 174.5
9′ 22.7 1.96, s 8′
a Acquired at 125 MHz, referenced to solvent signal meod4 at δ 49.15 ppm. b Acquired at 500 MHz, referenced
to solvent signal meod4 at δ 3.31 ppm. c Proton showing HMBC correlation to indicated carbons. d Overlapped
signals. e Observed in HMBC with CNST13 = 2 Hz.
Finally, the planar structure was deduced, as shown in Figure 2, which is in concordance with the
HR-ESI-MS data (measured 393.1509, calculated 393.1517, ∆ppm 2.0). The isolated compound was
named huimycin and was identified as a novel natural compound. Structurally, huimycin is closely
related to dapiramicins A and B, differing from the latter only in the sugar moiety attached to the
aglycone (Figure 2) [26,27].
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3.3. Determination of the Minimal Huimycin Gene Cluster
The presence of a 7-deazapurine moiety, typical of a pyrrolopyrimidine class of nucleoside
antibiotics [1], in the structure of the isolated huimycin indicates the participation of the expressed
nucleoside cluster in its production. The huimycin gene cluster was expressed in the heterologous
host strain as a part of the large 95-kb chromosomal fragment in BAC 2I16. To determine the minimal
set of genes required for huimycin biosynthesis, a sequence analysis and a series of gene deletion
experiments were performed.
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The sequence analysis of the DNA fragment cloned in BAC 2I16 leading to nucleoside production
revealed the presence of seven open reading frames, huiA – huiG (locus tags KALB_4067 – KALB_4073),
which are highly likely to be involved in huimycin biosynthesis (Figure 3, Table 2). Five of these genes
shared homology at the protein level with the genes within the biosynthetic cluster of toyocamycin—the
parent compound of the pyrrolopyrimidine class of antibiotics (Figure 2, Table 2) [28]. The huiA
gene, encoding a putative transcriptional regulator, shares homology with the regulatory gene
toyA [28]. The genes huiB, huiD, huiE and huiF encode putative 7-cyano-7-deazaguanine synthase,
6-carboxytetrahydropterin synthase, 7-carboxy-7-deazaguanine synthase and GTP cyclohydrolase I,
and they share homology with the toyocamycin biosynthetic genes toyM, toyB, toyC and toyD,
respectively (Table 2) [28]. The structural similarities between huimycin and toyocamycin also imply
similar biosynthetic routes leading to the production of antibiotics. The genes huiC and huiG do not have
counterparts in the toyocamycin gene cluster; they encode putative SAM-dependent methyltransferase
and glycosyltransferase, respectively (Table 2). The genes huiC and huiG are likely responsible for the
structural differences between huimycin and toyocamycin.
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The gene huiA encodes a transcriptional regulator and was assumed to constitute the 5′ outer
border of the huimycin cluster (Figure 3). The counterpart of the gene huiA within the toyocamycin
biosynthetic pathway, toyA, also constitutes the first gene of the cluster [28]. The deletion of the toyA
gene completely abolishes toyoc ycin production [29]. The first three genes in the region upstream of
the huiA gene, KALB_4064, KALB_4065, and KALB_4066 (Figure 3), encode an enhanced intracellular
survival protein and two hypothetical proteins, respectively. No function in nucleoside biosynthesis
could be assigned to these three genes. This further strengthens the assumption that the huiA gene
constitutes the 5′ boundary of the cluster. To corroborate this assumption empirically, the 20 kb DNA
fragment upstream of the huiA gene was deleted within the 2I16 BAC through RedET recombineering.
The obtained construct, 2I16_LS, resulted in huimycin production when it was transferred into an
S. albus strain. This clearly indicated that the genes in the upstream region of the huiA are not required
for huimycin biosynthesis. Thus, it is likely that the huiA gene is at the 5′ end of the huimycin
gene cluster.
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Prediction of the 3′ boundary of the huimycin cluster was not obvious from the gene annotation.
The last gene showing homology to toyocamycin biosynthetic genes is huiF (Table 2). This gene is
followed by the gene huiG, which encodes a glycosyltransferase that might participate in nucleoside
biosynthesis. The genes KALB_4074, KALB_4075, KALB_4076, KALB_4077, and KALB_4078 in the
downstream region of the huiG encode a putative carbamoyltransferase, pyridoxamine 5′-phosphate
oxidase family protein, SAM-dependent methyltransferase, and two glycosyltransferases, respectively.
As is evident in the huimycin structure (Figure 2), glycosyltransferase and methyltransferase activities
are required to produce huimycin. The required methyltransferase may be encoded either by huiC or
by KALB_4076. It is also not obvious which of the three glycosyltransferase genes, huiG, KALB_4077
or KALB_4078, participates in huimycin biosynthesis. To clarify this, the 36 kb DNA fragment
downstream of the KALB_4076 gene was deleted in the 2I16 BAC. The obtained BAC 2I16_RS led
to huimycin production when introduced into S. albus. This clearly indicates that the genes in the
downstream region of KALB_4076, including the two glycosyltransferase genes KALB_4077 and
KALB_4078, do not participate in huimycin biosynthesis. The possible participation of the genes
KALB_4074, KALB_4075, and KALB_4076 in huimycin biosynthesis was assessed by their inactivation
in the 2I16 BAC. The obtained BACs (2I16_4074, 2I16_4075 and 2I16_4076) contained the deletions
of the genes KALB_4074, KALB_4075 and KALB_4076, respectively, and they resulted in huimycin
production when introduced in S. albus. This shows that none of the inactivated genes is essential for
huimycin production. Thus, it is likely that the huiG gene is at the 3′ end of the huimycin gene cluster.
Deletion of the genes located outside the huiA – huiG fragment have been shown not to affect
the huimycin production in the heterologous strain S. albus. These genes are considered not to
participate in huimycin biosynthesis, however a possibility exists that some of the deleted genes are
crosscomplemented by one or several host genes. To demonstrate the importance of the huiA–huiG
fragment for nucleoside production, the huiC gene, encoding the methyltransferase, was deleted from
the 2I16 BAC. The deletion of the huiC gene completely abolished the production of the huimycin,
showing its involvement in the production of this nucleoside.
3.4. Biosynthesis of Huimycin
Seven genes, huiA–huiG, have been shown to be sufficient for huimycin production. The huiA
gene encodes a putative transcriptional regulator and is likely to be involved in the regulation of
expression of the huimycin biosynthetic gene cluster. The homolog of huiA, the toyA gene, encodes a
pathway-specific regulator of the toyocamycin gene cluster [28]. The six genes, huiB–huiG, encode
structural enzymes that catalyze huimycin biosynthetic steps. The products of the genes huiB, huiD,
huiE, and huiF display significant sequence similarity with the products of the toyocamycin biosynthetic
genes toyM, toyB, toyC, and toyD, respectively. The genes huiC and huiG have no homologs in the
toyocamycin cluster and encode a putative methyltransferase and glycosyltransferase, respectively.
The considerable sequence similarity between huimycin and toyocamycin gene clusters implies the
similarities in the biosynthetic routes leading to the production of the compounds.
Similar to toyocamycin, GTP is regarded as a main precursor for huimycin production [1,28].
The first reaction in huimycin biosynthesis is the conversion of GTP into 7,8-dihydroneopterin
triphosphate (H2NTP) (Figure 4). This reaction is catalyzed by the product of the gene huiF,
which encodes a putative GTP cyclohydrolase I. The product of the huiF gene shares 66% identity with
the product of the toyD gene, which also catalyzes the first step of the toyocamycin biosynthesis [1,28].
The second step in the pathway is catalyzed by 6-carboxytetrahydropterin synthase encoded by huiD,
which converts H2NTP into 6-carboxy-5,6,7,8-tetrahydropterin (CPH4) (Figure 4). The product of the
huiD gene shares 65% identity with the product of toyB, which is responsible for the similar reaction
in the toyocamycin biosynthesis [1,28]. The third biosynthetic step is catalyzed by the product of
the toyC homolog, huiE, which encodes 7-carboxy-7-deazaguanine synthase. This enzyme converts
CPH4 into 7-carboxy-7-deazaguanine (CDG) [1,28]. The products of toyC and huiE share 50% identity.
The last step common for both huimycin and toyocamycin biosynthesis is the conversion of the
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CDG into 7-cyano-7-deazaguanine (PreQ0) through the action of 7-cyano-7-deazaguanine synthase
(Figure 4). This enzyme is encoded by the toyM homolog, huiB. The protein products of these
genes share 72% identity. We propose that the last two enzymatic steps required for the conversion
of PreQ0 into huimycin are the methylation of 7-cyano-7-deazaguanine and the attachment of the
N-acetylglucosamine moiety (Figure 4). The methylation reaction is likely to be catalyzed by the
product of the gene huiC, which encodes a SAM-dependent methyltransferase. The attachment
of the N-acetylglucosamine to the 2-amino-6-methoxy-7-cyano-7-deazapurine is catalyzed by the
glycosyltransferase encoded by the last gene in the huimycin gene cluster – huiG. The order in which the
last two reactions take place in the huimycin biosynthesis is not known. The isolation of dapiramicin B
aglycone (2-amino-4-methoxy-5-cyanopyrrolo[2,3-d]pyrimidine) from the culture of Streptomyces sp.
MK63-43F2 implies that that methyltransfer reaction precedes glycosylation [30]. Huimycin is thus far
the only known member of the pyrrolopyrimidine class of compounds with an N-acetylglucosamine
moiety in its structure. Additionally, the position of the N-glycosidic bond distinguishes huimycin
from most of the 7-deazapurine nucleosides. Only in the structures of dapiramicin A and B, sugar
moieties are also attached to the amino group at the second position of the 7-deazapurine chromophore
(Figure 2) [26,27]. Furthermore, dapiramicin A and B share the same chromophore as huimycin.
Since the dapiramicin biosynthetic gene cluster has not yet been discovered, it is not possible to
study whether the structural similarities between huimycin and the dapiramicins are also reflected
on the DNA sequence level. The identified huimycin biosynthetic genes can be used to screen
sequenced genome databases to identify gene clusters potentially encoding pyrrolopyrimidines distinct
from toyocamycin.
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4. Conclusions
In this paper, we reported the identification and successful heterologous expression of the
gene cluster responsible for the production of huimycin, a new member of the pyrrolopyrimidine
family of nucleoside natural products. Huimycin features that are unique for nucleosides include
an N-acetylglucosamine moiety attached to the 2-amino-6-methoxy-7-cyano-7-deazapurine core.
The minimal set of huimycin biosynthetic genes was identified through a series of gene deletion
experiments. The expression of the huimycin gene cluster in S. albus reported here is the first example
of successful heterologous expression of a secondary metabolite pathway from the rare actinomycetal
genus Kutzneria.
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